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Morphological changes of the peritoneal membrane that
occur over time among patients on peritoneal dialysis
include fibrosis and neoangiogenesis. While the
pathophysiologic mechanisms underlying these changes
are not fully understood, the activation of the
renin–angiotensin–aldosterone system (RAAS) may have an
important role. Components of the RAAS are constitutively
expressed within peritoneal mesothelial cells, and are
upregulated in the presence of acute inflammation and
chronic exposure to peritoneal dialysate. The high glucose
concentration, low pH, and the presence of glucose
degradation products in peritoneal dialysis solutions have all
been implicated in modulation of peritoneal RAAS.
Furthermore, activation of the RAAS, as well as the
downstream production of transforming growth factor-b,
contributes to epithelial-to-mesenchymal transformation of
mesothelial cells, resulting in progressive fibrosis of the
peritoneal membrane. This process also leads to increased
vascular endothelial growth factor production, which
promotes peritoneal neoangiogenesis. Functionally, these
changes translate into reduced ultrafiltration capacity of the
peritoneal membrane, which is an important cause of
technique failure among patients on long-term peritoneal
dialysis. This brief review will describe our current state of
knowledge about the role of peritoneal RAAS in peritoneal
membrane damage and potential strategies to protect the
membrane.
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The renin–angiotensin–aldosterone system (RAAS) has long
been an important focus in nephrology because of its
involvement in renal injury across all stages of chronic
kidney disease. Its role in peritoneal membrane changes that
occur over time in patients on peritoneal dialysis (PD) is an
area of increasing interest. In this review, we will discuss the
changes that occur in the peritoneal membrane of patients on
PD, provide evidence for the presence of a local peritoneal
RAAS, and highlight its potential role in the pathogenesis of
progressive peritoneal membrane damage. We will also
discuss potential therapeutic strategies for the prevention of
this injury.
PERITONEAL MEMBRANE CHANGES IN PATIENTS ON PD
The peritoneal membrane consists of a mesothelial mono-
layer, under which lies the submesothelial compact zone.
This submesothelial layer consists of connective tissue
with interspersed fibroblasts, mast cells, and macrophages.
Within and deep to the submesothelial compact zone lie
the peritoneal capillaries. It is across these layers that the
processes of diffusion and ultrafiltration (UF) occur.
Importantly, although the rare entity of encapsulating
peritoneal sclerosis involves extensive changes within the
visceral peritoneum, the morphological changes that com-
monly occur with increasing time on PD are seen
predominantly within the parietal peritoneal membrane.1
Peritoneal membrane changes that occur in patients with
advanced chronic kidney disease and on PD have been
assessed in several peritoneal biopsy studies.2–6 In the largest
of these studies, using careful specimen processing, control
peritoneal biopsy samples obtained from living kidney
donors were compared with uremic samples from predialysis
patients and with samples from PD patients.5 These data
showed that uremic patients relative to controls exhibited
reactive mesothelial cell changes and an increased subme-
sothelial compact zone thickness. When biopsies from
uremic patients not on dialysis were compared with biopsies
from PD patients, it was found that PD patients had more
pronounced mesothelial cell changes, ranging from a reactive
appearance to mesothelial cell loss. In addition, the median
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thickness of the submesothelial compact zone increased from
40 mm in normal subjects to 150 mm in uremic patients and
to 270 mm in PD patients. Duration of PD therapy was also
associated with increased compact zone thickness. In
addition to these findings, prominent vascular changes were
seen among patients on PD, including progressive sub-
endothelial hyalinization with luminal narrowing or oblitera-
tion. These vascular changes, which involved venules to a
greater degree than arterioles, were increasingly prevalent
with time on PD, such that 89% of patients on PD for at least
6 years had evidence of vasculopathy.
Another important vascular change observed with time on
PD is peritoneal neoangiogenesis. This was first noted in the
early 1990s in autopsies of PD patients.7 It was subsequently
observed that rats exposed to daily infusions of standard
4.25% dextrose dialysis solution had significantly more
peritoneal neoangiogenesis relative to rats infused with
Ringer’s lactate.8 Human peritoneal biopsy data show an
increase in peritoneal vessel number with time on PD, with
the most vessels among those with peritoneal sclerosis.9 The
peritoneal membrane changes that occur with time in PD
patients are shown in Figure 1.
Although the presence of morphological changes within
the peritoneal membrane is not in and of itself meaningful, a
relationship between these morphological changes and
functional impairment of the peritoneal membrane in
patients on PD make these findings relevant. In a study
examining the changes in peritoneal membrane function over
time, Davies10 reported both an increase in small solute
transport and a reduction in peritoneal UF capacity over time
on PD. The more rapid removal of solute has been attributed
to peritoneal neoangiogenesis with a resultant increase in
effective peritoneal surface area, while the decline in UF is
likely multifactorial. Not only is there more rapid dissipation
of the glucose osmotic gradient as a result of the increased
blood vessel number, but there is also a simultaneous
reduction in the osmotic conductance of the membrane to
glucose as a result of progressive peritoneal membrane
fibrosis. UF failure remains an important cause of technique
failure among patients on long-term PD. In one series, UF
failure accounted for 24% of PD discontinuation overall, and
51% among those on PD for greater than 6 years.11,12
Understanding the basis for these peritoneal membrane
changes is therefore highly relevant to prolonging technique
survival in patients on PD.
LOCAL PERITONEAL RENIN–ANGIOTENSIN–ALDOSTERONE
SYSTEM
Although the systemic (or endocrine) RAAS is well under-
stood, it has become increasingly clear that many tissues are
able to locally synthesize all of the components of the RAAS.
One of the most studied examples of such tissues is the
kidney, where it has been shown that renal tubular cells
express renin and angiotensin.13 These locally produced
hormones then behave in an autocrine or paracrine manner,
and one result is upregulation of transforming growth
factor-b (TGF-b) and other factors such as aldosterone
that promote interstitial fibrosis.14–16
Similarly, peritoneal mesothelial cells appear to have their
own local RAAS. This has been shown in studies in which
cultured human peritoneal mesothelial cells were shown to
constitutively express angiotensinogen, angiotensin convert-
ing enzyme (ACE), the angiotensin II type 1 and type 2
receptors, as well as TGF-b and fibronectin.17,18
MEDIATORS OF PERITONEAL RAAS ACTIVATION
Although peritoneal mesothelial cells constitutively express
the genes of the RAAS and their effector cytokines, the
infusion of dialysate into the peritoneal cavity appears to
upregulate the expression of these genes. The basis for the
RAAS activation may relate to one or more components of
the bioincompatible solutions that are used, including the
high glucose concentration, hyperosmolality, low pH, high
lactate concentration, and the presence of glucose degrada-
tion products (GDPs).
One of the most important activators of the RAAS is
glucose. This is evidenced by the local RAAS activation that is
seen in multiple tissues in diabetic patients.19 PD patients
using conventional solutions have a local peritoneal micro-
environment that consists of glucose concentrations ranging
from 76 mmol/l (for a 1.5% dextrose solution) to 215 mmol/l
(for a 4.25% dextrose solution). Because mesothelial cells
have the capacity for glucose uptake,20 the glucose-rich
environment leads to intracellular signaling that results in
RAAS activation. It has been shown that exposing human











Figure 1 |Changes in the peritoneal membrane with time on
therapy. (a) Represents the peritoneal membrane at baseline.
(b) Represents changes over time on therapy. The mesothelial
monolayer undergoes injury and denudation with epithelial-to-
mesenchymal transition of mesothelial cells to a myofibroblast-
like appearance. The submesothelial compact zone increases in
thickness with increasing extracellular matrix deposition. In the
deeper, loose, adipose connective tissue lies the vascular network
that undergoes neovascularization and increased vasculopathy
characterized by arteriolar and venular hyalinization, luminal
distension, and obliteration.
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leads to upregulation of angiotensinogen, ACE, and angio-
tensin II receptor type 1 expression.17 Exposure to glucose
has also been shown to increase angiotensin II production
and secretion, leading to upregulation of TGF-b and
fibronectin expression, and the stimulation of vascular
endothelial growth factor (VEGF) and procollagen secre-
tion.21,22 The increase in TGF-b associated with peritoneal
glucose exposure may be further augmented in the presence
of mesothelial cell stretch or fluid shear stress.23
In addition to the high glucose concentration in standard
dialysis solutions, conventional peritoneal dialysate has an
acidic pH of approximately 5.4. The potential role of this
‘unphysiologic’ pH in RAAS activation was shown in a study
in which exposure of rats to acidic dialysate was associated
with peritoneal thickening and mesothelial cell loss, with
abrogation of this effect in the presence of systemic RAAS
blockade.24 The role of the acidic pH of dialysate and GDPs
was assessed in a study in which rats were treated with either
standard dialysate or neutral pH, low GDP dialysate. In this
study, TGF-b and VEGF expression, both of which are
upregulated by RAAS, were significantly increased in the
standard dialysate relative to the more biocompatible
dialysate, suggesting a role for low pH, GDPs or both in
dialysate-induced RAAS activation.25
Beyond the chronic exposure of the peritoneum to
unphysiologic dialysis solutions, acute inflammatory stimuli
such as peritonitis can activate the RAAS. Peritonitis has been
shown to cause marked upregulation of the expression of
angiotensin II in human peritoneal mesothelial cells, leading
to increased fibronectin expression.18 Furthermore, rat
models of PD peritonitis have shown the ability of peritonitis
to increase TGF-b levels and induce peritoneal fibrosis, and
the effectiveness of both irbesartan and spironolactone in the
mitigation of this fibrosis.26 The benefit of aldosterone
antagonism highlights the multiple mediators of the
profibrotic effects of RAAS activation, with contributions
from both angiotensin-II-mediated TGF-b production and
aldosterone.
ROLE OF PERITONEAL RAAS ACTIVATION IN PERITONEAL
MEMBRANE DAMAGE
On the basis of the above data, it is clear that peritoneal
RAAS activation leads to upregulation of profibrotic factors
such as TGF-b and angiogenic factors such as VEGF. Several
studies have shown the direct role of these factors in the
submesothelial compact zone fibrosis and neoangiogenesis
that is observed in PD patients. In an elegant gene transfer
study, Margetts et al.27 looked at the effect of overexpression
of TGF-b in rat peritoneal mesothelial cells on several
histologic and clinical endpoints. In this study, the rats
exposed to higher peritoneal TGF-b levels had an increased
submesothelial compact zone thickness. In addition, they had
higher effluent VEGF levels, along with increased peritoneal
blood vessel number and decreased net UF. This was followed
by another rat study involving transfer of antifibrotic and
antiangiogenic genes to the rat peritoneum.28 As expected,
expression of the antifibrotic gene, which produced a TGF-b-
inhibiting proteoglycan, dramatically reduced the degree of
compact zone fibrosis induced by exposure to standard
dialysate. In addition, expression of the antiangiogenic gene,
angiostatin, prevented the neoangiogenesis and improved the
UF dysfunction seen in the rats exposed to the dialysate. The
cascade of events that leads to UF dysfunction and membrane
failure is shown in Figure 2.
The mechanism by which TGF-b and other inflammatory
stimuli lead to peritoneal fibrosis and neoangiogenesis
appears to be the induction of the process of epithelial-to-
mesenchymal transition of peritoneal mesothelial cells.29,30
Specifically, with time on PD, mesothelial cells show a
progressive loss of epithelial phenotype and acquire myofi-
broblast-like characteristics that allow them to migrate into
the submesothelial compact zone and produce extracellular
matrix, along with elaboration of growth factors such as
VEGF. The stimuli for epithelial-to-mesenchymal transition,
reviewed in detail by Aroeira et al.,31 include inflammation,
advanced glycation end products, GDPs, low pH, mechanical
injury, hemoperitoneum, and angiotensin II. Because angio-
tensin II, acting both directly as well as indirectly via TGF-b
production, has been shown to be an important mediator of
this process,32 reducing RAAS activation may be of critical
importance in preventing or limiting the extent of epithelial-
to-mesenchymal transition.
Although the data are highly suggestive of a role for RAAS
activation in peritoneal membrane injury, it is important to
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Figure 2 |Peritoneal effects of the
Renal–Angiotensin–Aldosterone system (RAAS). Activation of
the RAAS is induced by a variety of local and systemic stimuli.
Local peritoneal autocrine/paracrine activity of the RAAS
stimulates mesothelial cell production of profibrotic and
pro-angiogenic cytokines leading to peritoneal membrane
neoangionesis, fibrosis and progressive peritoneal membrane
injury. Abbreviations: ACE, angiotensin converting enzyme; Ang-I,
angiotensin I; Ang-II, angiotensin II; AT1-R, angiotensin II type 1
receptor; AT2-R, angiotensin II type 2 receptor; GDP, glucose
degradation product; TGF-b, transforming growth factor-b; VEGF,
vascular endothelial growth factor; UF, ultrafiltration.
Kidney International (2010) 78, 23–28 25
SJ Nessim et al.: Role of local RAAS in peritoneal membrane injury m in i rev iew
short-term exposure to the potential mediators of the
RAAS, and almost all involved rats with intact renal function.
It is unknown whether these data can be extrapolated to
long-term exposure to dialysate in a uremic host.
POTENTIAL STRATEGIES FOR PERITONEAL MEMBRANE
PRESERVATION
Given the important role of the local peritoneal RAAS in the
peritoneal membrane damage that occurs over time in PD
patients, it follows that peritoneal injury may be abrogated or
prevented by targeting the peritoneal RAAS. Therapeutic
measures can be divided into (1) systemic blockade of the
RAAS and (2) strategies to decrease local peritoneal RAAS
activation.
Systemic RAAS blockade
The effect of RAAS blockade in the prevention of peritoneal
membrane damage has been studied in vitro, as well as in animal
and human studies. Although the majority of studies have
involved use of ACE inhibitors and angiotensin-receptor
blockers (ARBs), other agents that block the RAAS such as
direct renin inhibitors and aldosterone antagonists could also be
of potential benefit. In vitro, it has been shown that both
losartan and captopril inhibit glucose-induced TGF-b and
fibronectin expression in cultured human peritoneal mesothelial
cells.17 Further, addition of captopril results in a concentration-
dependent decrease in VEGF synthesis.33 These results were
supported by a study in which rats were administered either
intraperitoneal saline, 4.25% dextrose, or 4.25% dextrose in
combination with oral enalapril.34 In this study, the rats treated
with the ACE inhibitor had a dramatic reduction in the degree
of submesothelial fibrosis relative to those who were exposed to
dialysate alone. In addition, effluent TGF-b levels, which were
elevated in the rats exposed to dialysate, were undetectable in
the ACE inhibitor-treated rats. Another study by the same
authors showed that use of an ACE inhibitor or ARB had similar
beneficial effects on peritoneal morphology and function.35
The human data to date have been limited. The first study
to have looked at this retrospectively studied 66 patients who
were on PD for at least 2 years.36 Changes in transport status
over time were assessed in those who had been on ACE
inhibitors or ARBs, as well as those who were not on any
form of RAAS blockade. In this study, although small solute
transport increased with time on PD in the control group,
there was no appreciable change in transport status among
those on ACE inhibitors or ARBs. The same authors
subsequently examined changes in solute transport as well
as technique survival in a larger cohort of patients.37 Once
again, the group of patients who were on ACE inhibitors or
ARBs did not show the increased solute transport with time
on therapy seen in the controls. However, no difference in PD
technique survival was observed. In a recent retrospective
analysis, a powerful survival benefit in those PD patients who
received an ACE inhibitor or ARB was shown. However, the
association of these medications with peritoneal membrane
function was not examined.38
Although these studies are informative, there are no
studies in PD patients to date that have assessed the
longitudinal effect of RAAS blockade on peritoneal mem-
brane histology. Moreover, of critical importance, the retro-
spective nature of the human studies to date leads to
potential for residual confounding, in that those patients who
were on some form of RAAS blockade may have been
systematically different from those who did not receive these
agents. To avoid these biases, it is clear that randomized
controlled trials are needed. Because membrane failure only
accounts for a fraction of PD technique failure, large
numbers of patients would be required to have adequate
power to detect an effect of RAAS blockade on PD technique
failure. Furthermore, because many PD patients are already
on some form of RAAS blockade for evidence-based
indications such as vascular protection or preservation of
residual renal function, the smaller number of PD patients
eligible for randomization would make recruitment
more difficult and could potentially affect the generalizability
of the results.
Attenuation of local RAAS activation
Although systemic RAAS blockade may be an effective
strategy to preserve peritoneal membrane integrity, it has
been postulated that long-term use of more physiologic PD
solutions might reduce local RAAS activation. Use of a
‘glucose-sparing regimen’ substituting icodextrin or amino-
acid-based PD solutions could minimize the glucose-
mediated effects discussed above. Studies of human perito-
neal mesothelial cells incubated with icodextrin have shown
improvement in markers of mesothelial cell function and
proliferation.39 However, these results have been refuted by
other studies that have shown equal mesothelial cell
cytotoxicity when incubated with either icodextrin or
glucose-based PD solutions.40,41 In rats exposed to either
icodextrin or a 2.5% dextrose solution, the icodextrin-treated
rats showed a reduction in both peritoneal membrane
thickness and TGF-b staining on histologic examination.42
Furthermore, a recent study compared the effect of 8 weeks of
intraperitoneal exposure to 4.25% dextrose solution vs
icodextrin in diabetic rats with 5/6 kidney ablation.43 In this
study, as compared with the rats exposed to the dextrose
solution, the icodextrin-treated rats showed less of an
increase in submesothelial fibrosis and neoangiogenesis, as
well as reduced fibronectin, VEGF, and advanced glycation
end-product expression. Further data come from a subgroup
analysis of the European Automated PD Outcome Study,
which prospectively followed 177 anuric automated PD
patients for 2 years. In this study, those who were treated with
icodextrin vs glucose-based solution experienced a slower
increase in small solute transport over the course of the
2-year study period, despite more rapid peritoneal transport
status and worse peritoneal UF capacity at baseline.44
An alternative dialysis strategy would involve the long-
term use of neutral pH, low GDP solutions. In animal
models, use of neutral pH, low GDP dialysate has been
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associated with reduced TGF-b and VEGF expression,25 less
peritoneal fibrosis and neoangiogenesis, and less of an
increase in peritoneal transport status compared to conven-
tional dialysate.45 In human studies, several reports have
revealed higher levels of dialysate effluent CA-125 with the
use of the neutral pH solutions when compared to
conventional PD solutions.46,47 However, markers of perito-
neal membrane fibrosis such as dialysate effluent TGF-b and
procollagen I C-terminal peptide are not influenced by the
use of neutral pH, low GDP solutions.48 Of concern, several
randomized controlled trials have revealed a tendency to both
a reduction in peritoneal UF capacity and an increase in
peritoneal transport status with the use of the neutral pH,
low GDP solutions compared to conventional dialysis
solutions.46,47 Because long-term, prospective human data
are lacking and the cost of the newer solutions is higher than
conventional dialysate, it is difficult to make a recommenda-
tion at this time regarding the optimal dialysate regimen for
peritoneal membrane preservation.
Another avenue that has yet to be explored is the vitamin
D axis. Vitamin D is known to modulate RAAS activation in
other tissues, such as the kidney. Deficiency of vitamin D is
associated with upregulation of RAAS activity and vitamin D
supplementation has been shown to reduce RAAS
activation.49–51 Although it is known that most PD patients
are deficient in both 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D,52 any potential role for supplementa-
tion with active and/or inactive forms of vitamin D in
mitigating peritoneal RAAS activation has yet to be studied.
SUMMARY
Long-term PD is associated with both morphological and
functional changes within the peritoneal membrane.
Although the etiology of these changes is likely multifactorial,
there are in vitro, animal and human data to suggest an
important role for the RAAS in the pathogenesis of the
peritoneal membrane fibrosis and neoangiogenesis that
occurs over time. Although blockade of the RAAS using
ACE inhibitors and ARBs may be important in ‘peritoneo-
protection’, this approach requires further study. Additional
research is required to determine the optimal PD regimen
that will provide effective solute clearance and UF while
reducing local peritoneal RAAS activation and preserving
peritoneal membrane integrity.
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